Bicycle Therapeutics plc (NASDAQ: BCYC) stock closed at 31.6 per share at the end of the most recent trading day (a 1.31% change compared to the prior day closing price) with a volume of 66.43K shares and market capitalization of 760.86M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 81 people. Bicycle Therapeutics plc CEO is Kevin Lee.

The one-year performance of Bicycle Therapeutics plc stock is 94.8%, while year-to-date (YTD) performance is 76.04%. BCYC stock has a five-year performance of %. Its 52-week range is between 15.25 and 36.99, which gives BCYC stock a 52-week price range ratio of 75.21%

Bicycle Therapeutics plc currently has a PE ratio of -12.50, a price-to-book (PB) ratio of 5.85, a price-to-sale (PS) ratio of 87.36, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -30.93%, a ROC of -42.80% and a ROE of -48.78%. The company’s profit margin is -%, its EBITDA margin is -492.90%, and its revenue ttm is $9.50 Million , which makes it $0.39 revenue per share.

Of the last four earnings reports from Bicycle Therapeutics plc, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.72 for the next earnings report. Bicycle Therapeutics plc’s next earnings report date is 04th Aug 2021.

The consensus rating of Wall Street analysts for Bicycle Therapeutics plc is Strong Buy (1), with a target price of $45, which is +42.41% compared to the current price. The earnings rating for Bicycle Therapeutics plc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bicycle Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bicycle Therapeutics plc has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.00, ATR14 : 2.01, CCI20 : -86.17, Chaikin Money Flow : 0.03, MACD : 0.51, Money Flow Index : 87.59, ROC : -6.56, RSI : 43.72, STOCH (14,3) : 21.20, STOCH RSI : 0.09, UO : 44.26, Williams %R : -78.80), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bicycle Therapeutics plc in the last 12-months were: Kate Bingham (Sold 44 895 shares of value $1 526 466 ), Kevin Lee (Option Excercise at a value of $2 308 348), Kevin Lee (Sold 194 882 shares of value $6 217 756 ), Nicholas Keen (Sold 30 000 shares of value $934 843 ), Nigel Crockett (Option Excercise at a value of $945 474), Nigel Crockett (Sold 80 000 shares of value $2 592 140 ), Pierre Legault (Option Excercise at a value of $394 837), Pierre Legault (Sold 45 000 shares of value $1 382 621 )